Product
Quadrivalent Inactivated Influenza High Dose
2 clinical trials
2 indications
Indication
Influenza ImmunizationIndication
Healthy Control ParticipantsClinical trial
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2024-03-28
Clinical trial
A Phase II, Open-label Study to Assess the Safety and Immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 VaccineStatus: Completed, Estimated PCD: 2022-02-08